How Much Does One Month of Wegovy Cost in the UK?

The dose you're on changes the monthly cost significantly

Wegovy follows a gradual titration schedule: treatment opens at a low dose and steps upward over several months as your prescriber reviews how you're getting on. That matters for pricing because the monthly cost at an early dose can look very different from the cost at maintenance. A provider quoting a low headline figure may be showing you the starter-dose price, not the dose most people reach after three to six months of treatment.

It's worth spending thirty seconds on any provider's treatment page to check whether they list prices by dose or show a single monthly figure, and if it's the latter, asking which dose that covers. If you want a clear picture of how much Wegovy costs per month across the full titration schedule, that page walks through what each stage typically sets you back. Prices reported since mid-2025 (after Novo Nordisk's UK list-price adjustment) range roughly £149 to £375 a month by dose across the private market, though these figures shift and vary by provider. Our page on how much Wegovy costs per month breaks this down by dose tier in more detail, and our single-dose cost page explains how the pen format affects what you're billed.

The NICE appraisal of semaglutide (TA875) sets NHS eligibility criteria, but private provision sits outside those pathways, meaning you can access treatment without meeting the NHS threshold, subject to clinical suitability assessed by the prescriber.

What headline prices often leave out

A monthly price for a prescription medicine is almost never the whole story. Across the private weight-loss market, the listed pen price sometimes excludes: an initial consultation fee (charged separately on first order), prescription processing charges, delivery costs, and any form of clinical follow-up between orders. Some providers also operate on a subscription model, where the low headline figure comes with an auto-renewing commitment that's harder to exit than it looks.

These aren't minor extras. A consultation fee of £20–£50 per order, plus a delivery charge, can add meaningfully to what looks like a competitive monthly figure. And if aftercare isn't included, questions that arise between doses (about side effects, dose-increase timing, or what to do if a pen is delayed) may cost extra or go unanswered.

The Wegovy price breakdown page covers the components of a fair comparison. Our FAQs also address what to check before committing to any provider.

Why we're not the cheapest, and what that difference buys you

We're straightforward about this: cheapest isn't a race we entered. The single price at nume covers the consultation, the prescription, the medicine itself, free tracked next-working-day delivery, and seven-day-a-week aftercare. There's no subscription, no auto-renewal, and no fee that appears after the fact. Every repeat order is individually reviewed by a real prescriber before anything is dispensed, your consultation doesn't land in an automated queue.

Our pharmacy is GPhC-registered (premises number 9012878, verifiable at the GPhC online register), and Wegovy is sourced through the licensed UK supply chain. If you'd like to understand how we work or who reviews your treatment, our clinical team page and about us page explain both.

Current treatment pricing is shown on the treatment consultation page, we don't print per-pen prices in articles, because what you pay depends on the dose your prescriber confirms is appropriate for you.

For a prescription medicine, price is the wrong place to start

Wegovy contains semaglutide, a prescription-only medicine regulated by the MHRA. The MHRA has issued clear public warnings about counterfeit and illegally supplied weight-loss pens, some fake pens seized in the UK contained the wrong active ingredient entirely, and others were sold with no clinical assessment at all. The NHS guidance on weight management injections is explicit that these medicines should only be used under clinical supervision.

A significant under-cut on price is one of the clearest warning signs that supply chain or clinical oversight has been cut. That's not a theoretical risk, it's the basis for the MHRA's ongoing enforcement activity. The right filter for comparing providers isn't the monthly figure; it's whether the pharmacy is GPhC-registered, whether a prescriber personally reviews every order, and whether genuine medicine is being dispensed from the licensed supply chain.

If you want to understand more about what one month of treatment typically involves clinically, the one-month weight loss page covers what the trial evidence says about early progress, and our broader weight loss treatment overview puts Wegovy in context alongside other licensed options.